REFERENCES
- Alkibay T, Karabas Ö, Hizel N, Bozkirli I. Urinary Glycosaminoglycan excretion following extracorporeal shock wave lithotripsy. Int Urol Nephrol 1993; 25: 321–326.
- Aso Y, Anderson L, Soloway M, et al. Prognostic factors in superficial bladder cancer. Prog Clin Biol Res 1986; 221: 257–269.
- Balish MJ, Jensen J, Uehling DT. Bladder mucin: a scanning electron microscopy study in experimental cystitis. J Urol 1982; 128: 1060–1063.
- Bernard AM, Ouled A, Roels H, Lauwerys R, Vandeleene B, Lambert A. Lack of relationship between urinary glycosaminoglycans and indices of tubular or glomerular renal damage. Nephron 1988; 48: 82–83.
- Bichler K-H, Sallis J, Brörling S. Observations on urinary glycosaminoglycan concentration in relation to the type of calculus and its tissue location, and to tissue tumours: In Brockis JG, Finlayson B, eds. Urinary Calculus. Littleton, Masscahusetts: PSG Publishing Co., 1981: 335–340.
- Bodenstab W, Kaufman J, Parsons CL. Inactivation of antiadherence effect of bladder surface glycosaminoglycan by a complete urinary carcinogen (N-methyl-N-nitrosurea). J Urol 1983; 129: 200–201.
- Bodenstab W, Stauffer C, Schmidt JD, Parsons CL. Protective effects of bladder surface glycosaminoglycans against carcinogenic agents (Abstract No 64:93). AUA, Inc. Annual Meeting 1982.
- Curran KL, Kupchella CE, Tamburro CH. Urinary glycosaminoglycan patterns in angiosarcoma of the liver. Cancer 1977; 40: 3050–3053.
- Friman C, Juvani M. Urinary excretion of glycosaminoglycan in malignant diseases of the haemopoietic and lymphatic tissues. Acta Med Scand 1975; 198: 115–122.
- Hennessey PT, Hurst RE, HemstreetIII GP, Cutter G. Urinary glycosaminoglycan excretion as a biochemical marker in patients with bladder carcinoma. Cancer Res 1981; 41: 3868–3873.
- Hopwood JJ, Dorfman A. Glycosaminoglycan synthesis by Wilms' tumour. Pediatr Res 1978; 12: 52–56.
- Jackson RL, Busch SJ, Cardin AD. Glycosaminoglycans: Molecular properties, protein interactions, and role in physiological processes. Physiol Rev 1991; 71: 481–539.
- Jakse G, Loidl W, Seeber GHofstadter F. Stage T1, grade 3 transitional cell carcinoma of the bladder: an unfavorable tumour? J Urol 1987; 137: 39–43.
- Karlsen SJ, Smevik B, Klingenberg Lund K, Berg KJ. Do extracorporeal shock waves affect urinary excretion of glycosaminoglycans? Br J Urol 1991; 67: 24–28.
- Klimberg IW, Wajsman Z. Treatment of muscle invasive carcinoma of the bladder. J Urol 1986; 136: 1169–1175.
- Kojima J, Nakamura N, Kanatani M, Ohmori K. The glycosaminoglycans in human hepatic cancer. Can Res 1975; 35: 542–547.
- Mbuyi JM, Dequeker J, Teblick M, Merlevede M. Relevance of urinary excretion of alcian-blue-glycosaminoglycans complex and hydroxproline to disease activity in rheumatoid arthritis. J Rheumatol 1982; 9: 579–583.
- Meares EM. Non-invasive carcinoma of the bladder. J Urol 1972; 107: 394–395.
- Nakajima M, Irimura T, Di Ferrante N, Nicolson GL. Metastatic melanoma cell heparanase. Characterization of heparan sulphate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem 1984; 259: 2283–2290.
- Nemec RE, Toole BP, Knudson N. The cell surface hyaluronate binding sites of invasive human bladder carcinoma cells. Biophysic Res Comm 1987; 149: 249–257.
- Parish CR, Coombe DR, Jakobsen KB, Bennet FA, Underwood PA. Evidence that sulphated polysaccharides inhibit tumour metastasis by blocking tumour-cell-derived heparanases. Int J Cancer 1987; 40: 511–518.
- Parsons CL, Greenspan C, Moore SW, Mulholland SG. Role of surface mucin in primary antibacterial defence of bladder. Urology 1977; 9: 48–52.
- Parsons CL, Stauffer C, Schmidt JD. Bladder surface glycosaminoglycans: an efficient mechanism of environmental adaptation. Science 1980; 208: 605–607.
- Pauwels RP, Smeets WW, Geraedts JP, Debruyne FM. Cytogenetic analysis in urothelial cell carcinoma. J Urol 1987; 137: 210–215.
- Richards B, Aso Y, Bollack C, et al. Prognostic factors in infiltrating bladder cancer. Prog Clin Biol Res 1986; 221: 271–286.
- Ro JY, Staerkel GA, Ayala AG. Cytologic and histologic features of superficial bladder cancer. Urol Clin North Am 1992; 19: 435–452.
- See WA, Chapman PH. Heparin prevention of tumour cell adherence and implantation on injured urothelial surfaces. J Urol 1987; 138: 182–186.
- Shrom SH, Parsons CL, Mulholland SG. Role of urothelial surface mucoprotein in intrinsic bladder defense. Urology 1977; 9: 526–533.
- Strisciuglio P, Fiorillo A, Costabile M, Montini T. Urinary excretion of glycosaminoglycans in neoplastic diseases of children, Eur J Pediatr 1989; 148: 584.
- Thome ID, Resnick MI. A methodology for the characterization of urinary glycosaminoglycans. J Urol 1984; 131: 995–999.
- Uehling DT, Kelley E, Hopkins WJ, Balish E. Urinary glycosaminoglycan levels following induced cystitis in monkeys. J Urol 1988; 139: 1103–1105.
- Van Every MJ, Sago AL, Ehler WJ, Novicki DE. Sucralfate inhibition of tumour cell implantation in the murine urinary bladder. J Urol 1988; 140: 188–190.
- Waxier B, Eisenstein R, Battifora H. Electrophoresis of tissue glycosaminoglycans as an aid in the diagnosis of mesotheliomas. Cancer 1979; 44: 221–227.
- Weinstein RS, Coon JS, Pauli BU. Characterization of urinary bladder cancer cells, In: Smith PH, Prout GR, eds. Bladder Cancer. First edition. Sevenoaks Butter-worths, 1983: 12–31.
- Weldon TE, Soloway MS. Susceptibility of urothelium to neoplastic cellular implantation. Urology 1975; 5: 824–827.
- Whiteman P. The quantitative measurement of alcian blue glycosaminoglycan complexes. Biochem J 1973; 131: 343–350.
- Yamaguchi Y, Ruoslahti E. Expression of human proteoglycan in Chinese hamster ovary cells inhibits cell proliferation. Nature 1988; 336: 244–246.